CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 132 enrolled
Drug / intervention
Buprenorphine Extended-Release Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05704543
NCT05704543Phase 4Completed
CompareCT.gov

A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of SUBLOCADE at Alternative Injection Locations in Adults

Indivior Inc.·interventional·Posted Jan 30, 2023·Updated Jan 7, 2025

In Brief

A Phase 4 clinical trial evaluating Buprenorphine Extended-Release Injection for Opioid Use Disorder. Completed, enrolled 132 participants across 6 sites.

Detailed Summary

Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD). Having alternative injection sites is desirable to provide additional flexibility to patients, particularly for those who may prefer less visible or more convenient injection locations. The primary objective of this study is to assess the relative bioavailability of extended-release buprenorphine when administered at alternative injection locations (test treatments), in comparison to the abdomen (reference treatment).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJan 30, 2023
Enrollment StartMar 1, 2023
Primary CompletionNov 1, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.4 years ago

Interventions

Buprenorphine Extended-Release Injectiondrug

Administered as a subcutaneous injection.